Gilenya (jill-LEN-nee-ya, fingolimod) is the first ORAL drug to reduce relapses in relapsing multiple sclerosis (MS)
November 2010
Please see the May 2012 FDA safety communication concerning Gilenya
Gilenya (jill-LEN-nee-ya, fingolimod) is the first ORAL drug to reduce relapses in relapsing multiple sclerosis (MS).It's a new immune modulator that prevents some white blood cells from migrating to the CNS and damaging it.
Gilenya is approved for first-line use...but don't expect it to replace beta-interferons (Avonex, etc) or Copaxone (glatiramer). These drugs have a longer safety record and they're less expensive.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote